146 related articles for article (PubMed ID: 7696185)
1. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line.
Langton-Webster BC; Xuan JA; Brink JR; Salomon DS
Cell Growth Differ; 1994 Dec; 5(12):1367-72. PubMed ID: 7696185
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.
Hancock MC; Langton BC; Chan T; Toy P; Monahan JJ; Mischak RP; Shawver LK
Cancer Res; 1991 Sep; 51(17):4575-80. PubMed ID: 1678683
[TBL] [Abstract][Full Text] [Related]
3. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
4. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
[TBL] [Abstract][Full Text] [Related]
5. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
6. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
7. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
Donato NJ; Perez M; Kang H; Siddik ZH; Ling YH; Perez-Soler R
Clin Cancer Res; 2000 Jan; 6(1):193-202. PubMed ID: 10656450
[TBL] [Abstract][Full Text] [Related]
8. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
10. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
11. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
14. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
16. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
17. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
18. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics.
Nilsson EE; Westfall SD; McDonald C; Lison T; Sadler-Riggleman I; Skinner MK
Cancer Chemother Pharmacol; 2002 Feb; 49(2):93-100. PubMed ID: 11862422
[TBL] [Abstract][Full Text] [Related]
19. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line.
Koropatnick J; Kloth DM; Kadhim S; Chin JL; Cherian MG
J Pharmacol Exp Ther; 1995 Dec; 275(3):1681-7. PubMed ID: 8531144
[TBL] [Abstract][Full Text] [Related]
20. Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin.
Marverti G; Giuseppina Monti M; Pegg AE; McCloskey DE; Bettuzzi S; Ligabue A; Caporali A; D'Arca D; Moruzzi MS
Carcinogenesis; 2005 Oct; 26(10):1677-86. PubMed ID: 15905201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
